| February 1 |
AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective
Capabilities |
| February 1 |
AstraZeneca PLC - Fourth Quarter and Full Year Results 2006 |
| February 1 |
Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon
Obtained Patent By Inequitable Conduct |
| February 1 |
Fresenius Medical Care and Amgen Enter New Commercial Collaboration
in Europe |
| February 1 |
Fresenius Medical Care and Amgen Establish a Joint Research Program
in Europe |
| February 1 |
FDA Sends MGI Pharma Letter Over Gliadel Wafer Advertisement |
| February 1 |
Ligand Announces Corporate Restructuring |
| February 1 |
Conor Medsystems Stockholders Approve Merger Agreement with Johnson
& Johnson |
| February 1 |
Strides Arcolab's JV acquires Farma Plus, Norway |
| February 1 |
Intellect Neurosciences, Inc. Converts into a Public Company
Through Merger Transaction with GlobePan Resources, Inc. |
| February 1 |
Alembic Acquires Non-Oncology Business of Dabur Pharma Ltd. |
| February 1 |
Pfizer to Acquire BioRexis to Access Novel Technology Platform and
Early Stage Diabetes Pipeline |
| February 1 |
FDA Announces Important Changes to Fuzeon Product Labeling |
| February 1 |
Astellas Will Offer an Early Retirement Program to Japanese
Employees |
| February 1 |
Grifols Announces FDA Approval of Alphanate to Treat von Willebrand
Disease |
| February 1 |
EaglePicher Pharmaceutical Services Acquired by Aptuit |
| February 1 |
Hospira Completes Acquisition of Mayne Pharma, Announces New
Commercial Leadership Structure |
| February 2 |
Numira Biosciences and Visual Influence Announce Merger |
| February 2 |
Eli Lilly Japan and Shionogi to Co-Develop and Co-Market Duloxetine
in Japan |
| February 2 |
GlaxoSmithKline Receives Approvable Letter for New Indications for
Arixtra (Fondaparinux Sodium) Injection |
| February 2 |
Accelrys Announces Pfizer Inc. as the First Member of the
Enterprise Cheminformatics Consortium |
| February 2 |
CSL Behring and Bayer Extend Agreement for Supply of Helixate
Recombinant Coagulation Factor |
| February 2 |
Texas Hormone Therapy Lawsuit Has Been Dismissed |
| February 2 |
Anacor Signs Worldwide Exclusive License Agreement With
Schering-Plough for AN2690, a New Topical Anti-Fungal Treatment |
| February 2 |
GTx's Phase III Clinical Development of Acapodene on Course
Following Planned Safety Review |
| February 2 |
FDA MedWatch - Lucentis (ranibizumab injection) - Preliminary
Safety Information From a Planned Interim Analysis In an On-Going
Study (SAILOR Study) |
| February 2 |
China Health Holding Acquires Majority Stake in Beijing Boran
Pharmaceutical |
| February 2 |
Schering-Plough Cites Today's Anacor Agreement as Latest in Series
of Deals |
| February 2 |
Valtrex (valacyclovir) - US Patent Litigation Update |
| February 2 |
Mitsubishi Pharma Corporation Reaches a Basic Agreement to Merge
with Tanabe Seiyaku Co., Ltd. |
| February 2 |
FDA Approves New Dosing Recommendations for Rapamune in High
Immunologic Risk Renal Transplant Patients |
| February 2 |
All Global is Acquired by WPP |
| February 2 |
Common Blood Pressure Drug Reduces Progressive Muscle Degeneration
in Mice |
| February 5 |
Arena Pharmaceuticals Completes Enrollment with 3,182 Patients in Lorcaserin Phase 3 Trial for Obesity |
| February 5 |
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration
to Develop Hemophilia Therapies |
| February 5 |
AstraZeneca Licenses Regeneron's VelocImmune Technology for
Discovering Human Monoclonal Antibodies |
| February 5 |
ImClone Systems Incorporated and Bristol-Myers Squibb Announce
Application In Japan for Use of Erbitux in Metastatic Colorectal
Cancer |
| February 5 |
Roche Continues to Strengthen Research and Development Focus on
Disease Biology Areas to Enhance Alignment of R&D |
| February 5 |
elbion and Wyeth Enter Collaboration to Develop New Treatments for
Schizophrenia |
| February 5 |
UTEK Corporation and CytoDyn, Inc. Complete Technology Transfer |
| February 5 |
Impax Files Revised Submission with Office of the Chief Accountant
of the SEC |
| February 5 |
Phase III Trial of Progesterone for the Prevention of Preterm Birth
in Women with a Previous Preterm Birth Earlier than 35 Weeks Does
Not Meet Endpoints |
| February 5 |
Wyeth Pharmaceuticals and MediVas Announce Research Partnership to
Develop Advanced Hemophilia Therapies |
| February 5 |
AXM Pharma Announces Acquisition of Leading Chinese Research
Institute |
| February 5 |
Mitsubishi Chemical Holdings: Business Results for the Third
Quarter of the Fiscal Year Ending March 31, 2007 |
| February 5 |
President’s FY 2008 Budget Advances FDA’s Public Health
Goals, Including Improving Safety of Nation’s Food Supply |
| February 6 |
ImClone Systems Opts-out of Development Agreement with UCB to Focus
Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B |
| February 6 |
ViaCell Announces CB001 Phase I Results |
| February 6 |
KineMed and Bayer Healthcare AG Enter Collaboration to Discover New
Therapeutic Applications for Drug Candidates |
| February 6 |
Migenix Provides Update on License-Option Agreement with
Schering-Plough for Celgosivir in Hepatitis C |
| February 6 |
Eisai Confirms Application for Judicial Review of NICE |
| February 6 |
Laureate Pharma Announces Collaboration With Boehringer Ingelheim |
| February 6 |
Genta Announces the Company Will Appeal FDA Action on New Drug
Application of Genasense in Chronic Lymphocytic Leukemia |
| February 6 |
UCB Gains Global Rights Pertaining to VEGFR-2 for CDP-791 |
| February 6 |
Global Agreement for HuMax-CD20 Receives Antitrust Clearance |
| February 6 |
Abbott to Initiate First Study to Evaluate Xience V Everolimus
Eluting Coronary Stent System in Treatment of Women with
Cardiovascular Disease |
| February 6 |
WEHI Enters Research Collaboration With Genentech to Develop New
Cancer Drugs |
| February 6 |
Ranbaxy Signs a New R&D Agreement with GSK |
| February 6 |
Orion Updates Progress with Simdax (i.v. levosimendan) |
| February 6 |
Jerini Expands Collaboration with Baxter to Develop
Non-intraveneous Hemophilia Therapy |
| February 6 |
Abbott Statement Regarding CMS' Proposed Expansion of Coverage for
Carotid Artery Stenting |
| February 6 |
Bio-Imaging Completes the Acquisition of Theralys SA of Lyon,
France |
| February 6 |
Strategic Planning for Discovery, Development and Clinical
Operations in China, India and other Emerging Regions |
| February 7 |
Forest Laboratories Announces Termination of Agreement for
Faropenem |
| February 7 |
Roche Posts Outstanding Results for 2006 |
| February 7 |
FDA Public Health Advisory: Life-Threatening Side Effects with the
Use of Skin Products Containing Numbing Ingredients for Cosmetic
Procedures |
| February 7 |
Drug Used in Coronary Artery Bypass Graft Surgery May Increase Risk
of Death |
| February 7 |
Return on Investment for Pediatric Exclusivity Program Varies
Widely for Pharmaceutical Companies |
| February 7 |
Inex Pharmaceuticals Announces Court of Appeal Win |
| February 7 |
Replidyne and Forest End Faropenem Collaboration |
| February 7 |
Baxter Receives Clearance From U.S. FDA for Ipump Pain Management
System 510(k) |
| February 7 |
Bayer Responds to Study and Commentary Published in Journal of
American Medical Association |
| February 7 |
Cambrex Completes Sale of Bio Businesses |
| February 7 |
Celtic Pharma Terminates Transmid Trial KSB311R/CIII/001 |
| February 7 |
GlaxoSmithKline Accepts Shares in Tender Offer for Shares of
Praecis Pharmaceuticals and Commences Subsequent Offering Period |
| February 7 |
IACP Calls on NAMS to Disclose Financial Ties to Wyeth |
| February 7 |
Polydex Pharmaceuticals Issues Interim Report on Business
Operations |
| February 7 |
New Analysis Shows That Intensive Lipitor Therapy Cuts the Risk of
Hospitalizations Due to Heart Failure in Patients with Coronary
Heart Disease |
| February 7 |
CDC, FAA, NIH, FDA, FBI and USDA Get the Highest Ratings of
Thirteen Federal Government Agencies |
| February 8 |
FDA Approves Orlistat for Over-the-Counter Use |
| February 8 |
Centocor, Inc. Releases Phase 2 Data on Novel Biologic CNTO 1275
Targeting Chronic Plaque Psoriasis |
| February 8 |
Glaxosmithkline and Fabre-Kramer Pharmaceuticals Enter Global
Agreement for New Treatment of Major Depressive Disorder |
| February 8 |
Baxter Continues Collaborations With Global Health Authorities to
Advance Pandemic Preparedness |
| February 8 |
Daiichi Sankyo Returns Development Rights of KAI-9803 |
| February 8 |
FDA Approves alli (orlistat 60 mg capsules) Over-The-Counter |
| February 8 |
Standard Therapy More Effective Than Diabetes Drug for Achieving
Pregnancy in Common Fertility Disorder |
| February 8 |
GlaxoSmithKline Delivers Strong 2006 Performance with Full Year EPS
Up 19% CER (16% Reported) |
| February 8 |
SEC Charges Family With a $3.7 Million Insider Trading Scheme |
| February 8 |
Pfizer's Sutent Receives FDA Approval to Include New First-Line
Advanced Kidney Cancer Data in Label |
| February 9 |
Gilead and Achillion Announce Positive Antiviral Activity of NS4A
Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development |
| February 9 |
Zeria, Kyowa Hakko in Japan Co-development and Co-marketing
Agreement for Asacol for Inflammatory Bowel Disease |
| February 9 |
Medal Program Showed Arthritis Patients Taking Arcoxia (etoricoxib)
Experienced Significantly Fewer Upper Gastrointestinal Events
Compared to Diclofenac |
| February 9 |
Lovenox Patent Infringement Suit Decided Against Sanofi-Aventis |
| February 9 |
Biota Holdings Announces Q2 Royalties from Relenza Grow to $7.3M |
| February 9 |
Inflazyme Pharmaceuticals Announces Corporate Restructuring |
| February 9 |
Nuvo Announces Update on Discussions With FDA Related to Approval
of Pennsaid |
| February 9 |
Genedata Expands Collaboration with HepatoSys Systems Biology
Network |
| February 12 |
NicOx Presents Promising Pre-Clinical Results on an NO-Donating
Latanoprost Derivative From Its Glaucoma Collaboration With Pfizer |
| February 12 |
Watson and GlaxoSmithKline Settle Lawsuit Over Wellbutrin Xl |
| February 12 |
Adeza to Be Acquired by Cytyc for $24 Per Share |
| February 12 |
AIDS Healthcare Foundation Bans Pfizer’s Drug Reps From Its
Clinics |
| February 12 |
Nexavar Shown to Significantly Extend Survival for Patients with
Advanced Liver Cancer |
| February 12 |
Forbes Medi-Tech Announces Next Steps in Pharmaceutical Development
and Corporate Restructuring |
| February 12 |
New Campaign Champions Changes in Medical Prescribing to End
Conflicts of Interest |
| February 12 |
Cell Therapeutics, Inc. Spin-off to Use Proprietary Recombinant
Genetic Technology to Develop Novel Biopharmaceuticals |
| February 12 |
FDA Announces Label and Indication Changes for the Antibiotic Ketek |
| February 12 |
Sanofi-Aventis Announces Update to U.S. Prescribing Information for
Ketek (Telithromycin) |
| February 12 |
Commonwealth Biotechnologies, Inc. Completes Acquisition of
Mimotopes Pty Ltd |
| February 12 |
Ranbaxy Launches Atorvastatin in Denmark |
| February 13 |
Boston Scientific Welcomes New England Journal of Medicine Articles
on Drug-Eluting Stents |
| February 13 |
Johnson & Johnson Statement on Voluntary Disclosure |
| February 13 |
Multiple Articles in the New England Journal of Medicine Confirm
On-Label, Long-Term Safety and Efficacy of the Cypher
Sirolimus-Eluting Coronary Stent Compared to Bare Metal Stents |
| February 13 |
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the
U.S. and Europe |
| February 13 |
Sanofi-aventis 2006: In a Difficult Environment, Another Year of
Growth in Adjusted EPS Excluding Selected Items |
| February 13 |
Teva Reports Fourth Quarter and Full Year 2006 Results |
| February 13 |
Novartis, The Broad Institute, and Lund University Announce Release
of Genome-wide Analysis of Genes Associated with Type 2 Diabetes
and Related Metabolic Disorders |
| February 13 |
Organon and Pharmacopeia Enter Into Discovery, Development and
Commercialization Alliance |
| February 13 |
Ingenuity Systems Announces Extension and Expansion of its
Licensing Agreement with Merck |
| February 13 |
ChemDiv to Provide Merck KGaA With Discovery Chemistry in Multiyear
Agreement, Extending Ongoing Collaboration |
| February 13 |
Rimonabant USA: Update |
| February 13 |
Generic Anti-Cholesterol Drugs Save $126 Million for Plan Sponsors,
Patients |
| February 13 |
Three Companies Consolidate under Holding Company |
| February 13 |
Prescriptions for Cholesterol Drugs Rise with New Generics |
| February 14 |
Study Published in The New England Journal of Medicine: 55 Percent Fewer Cases of Flu in Young Children Vaccinated With FluMist Vs. Flu Shot |
| February 14 |
Merck Updates Prescribing Information for Rotateq, the Company's
Vaccine to Help Prevent Rotavirus Gastroenteritis in Infants and
Children |
| February 14 |
Favrille Announces Agreement With Berlex, Inc. Regarding Use of
FavId in Combination With Leukine (sargramostim) in B-Cell
Non-Hodgkin's Lymphoma |
| February 14 |
Halozyme And Baxter Expand Global Hylenex Collaboration |
| February 14 |
Daiichi Sankyo Announces Midterm Management Plan for Fiscal
2007-2009 |
| February 14 |
Dainippon Sumitomo Pharma Co., Ltd.:Launch of 'Replagal 3.5 mg' for
Anderson-Fabry Disease |
| February 14 |
Merck Settles Tax Dispute with Internal Revenue Service |
| February 14 |
Genzyme Reports Financial Results for Fourth Quarter of 2006 and
Full Year |
| February 14 |
Advancis Pharmaceutical Announces FDA Decision That its Amoxicillin
Pulsys NDA is Not Complete |
| February 14 |
Telik Announces Corporate Restructuring |
| February 14 |
Biovail Issues Statement on Reports of Conclusion of SEC Gradient
Investigation |
| February 14 |
Eli Lilly and Company Statement: Judge Grants Lilly's Request for a
Permanent Injunction Involving Misleading Selection of Illegally
Leaked Lilly Documents |
| February 14 |
Abraxis Bioscience Completes Acquisition of Manufacturing Complex
from Pfizer |
| February 14 |
Merck & Co., Inc., Again Reduces Price of Stocrin (efavirenz)
for Patients in Least Developed Countries and Countries Hardest Hit
by Epidemic |
| February 15 |
Akzo Nobel Annual Results 2006: Record Year |
| February 15 |
Biogen Idec Reports Full Year and Fourth Quarter 2006 Results |
| February 15 |
Novartis Seeking Clarity in Indian Patent Laws, a Critical
Incentive for Long-Term R&D Investments Into Better Medicines
for Patients |
| February 15 |
Sanofi pasteur to License Single Dose Japanese Encephalitis Vaccine
from Acambis |
| February 15 |
2006 : Another Record Year for Solvay, Due to Strong Growth in
Operating Performance |
| February 15 |
FDA Accepts Two Supplemental New Drug Applications to Expand the
U.S. Labeling for Januvia |
| February 15 |
GlaxoSmithKline Extends Subsequent Offering Period By One Day |
| February 16 |
FDA Alerts Consumers to Unsafe, Misrepresented Drugs Purchased Over the Internet |
| February 16 |
Ranbaxy: Press Statement |
| February 16 |
Wyeth Wins Little Rock Hormone Therapy Trial |
| February 16 |
GPC Biotech Submits NDA for Lead Oncology Drug Candidate
Satraplatin |
| February 16 |
Closing of Boehringer Ingelheim`s Divestiture of Pharmaton SA to
Ideasphere Cancelled |
| February 16 |
First and Only Treatment Now Available for Mild-to-Moderate
Parkinson's Disease Dementia |
| February 16 |
Roche Files Application in Europe for Tamiflu 30 and 45 Mg Capsules |
| February 16 |
GlaxoSmithKline Successfully Completes Tender Offer for Shares of
Praecis Pharmaceuticals |
| February 16 |
Advanced Magnetics Announces Settlement of Lawsuit with Cytogen
Corporation |
| February 16 |
InSite Vision Announces Patent Agreement With Pfizer |
| February 16 |
Inspire Licenses AzaSite For Ocular Infections |
| February 16 |
European Approval of HIV Drug darunavir Will Provide a Potent New
Option With Fuzeon for Treatment-Experienced Patients |
| February 16 |
Anti-HIV Medication Prezista Receives Conditional Marketing
Authorisation in the European Union |
| February 16 |
FDA Sends Abraxis BioScience Warning Letter Over Manufacturing
Problems |
| February 19 |
WHO reports some promising results on avian influenza vaccines |
| February 19 |
Non-Insecticide Lice Treatment Kills Lice by Asphyxiation |
| February 20 |
Shire plc: On Time Execution of Operating Plan Delivers Strong 2006
Performance |
| February 20 |
Shire Agrees to Acquire New River to Gain Full Control of Vyvanse,
its Future Flagship Product for ADHD |
| February 20 |
New River Pharmaceuticals to be Acquired by Shire plc for $64 Per
Share |
| February 20 |
Shire Announces US$800 Million Equity Financing in Connection With
Acquisition of New River |
| February 20 |
New AARP Poll Shows 86% of Americans Over 18 Believe Medicare
Should Have Bargaining Power for Prescription Drugs |
| February 20 |
Bristol-Myers Squibb Completes Land Acquisition for New Biologics
Facility |
| February 20 |
SAFE Standard and Arcot Software Used By AstraZeneca to Submit
First Digitally Signed Submission to FDA |
| February 20 |
Entelos and Organon Extend Research Agreement |
| February 20 |
Cancer Drug Can Extend Survival in Patients with Deadly Brain
Tumors |
| February 20 |
MIV Therapeutics Completes Acquisition of Biosync Scientific to
Expand Operations and Accelerate Commercialization in Fast-Growing
Markets |
| February 20 |
Philadelphia Hormone Therapy Trial Completed |
| February 20 |
Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck
& Co., Inc. |
| February 20 |
Plaintiffs Win Another Prempro Case in Philadelphia; Wyeth Loses
Second Hormone Therapy Drug Case |
| February 20 |
FDA Warns About Erythropoiesis Stimulating Agents (ESAs) - Results
of Aranesp Study May Apply to Other ESAs |
| February 21 |
Pharmacyclics Receives Refuse to File Letter for Xcytrin |
| February 21 |
King Pharmaceuticals Announces FDA Approval of New Bicillin
Manufacturing Facility |
| February 21 |
TransTech Pharma, Inc. Obtains Exclusive License to Glucokinase
Activator Program for the Treatment of Diabetes from Novo Nordisk |
| February 21 |
New Storage Instructions Approved for Byetta |
| February 21 |
CSL Ltd.: Interim Result - Strong Profit from Operations, Up 46% to
$257 Million |
| February 21 |
Dyax and Genzyme Announce Agreement to Terminate Joint Venture for
the Commercialization of DX-88 in HAE |
| February 21 |
Vaccine Safety Group Releases Gardasil Reaction Report |
| February 21 |
Merck KGaA: Karl-Ludwig Kley to Succeed Michael Roemer as Chairman
of the Executive Board |
| February 21 |
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta
Pharmaceuticals |
| February 21 |
Comprehensive Company, Brand, and Pipeline Database Now Provides
Company-wide Access |
| February 21 |
GlaxoSmithKline Advises Health Officials on Avandia |
| February 21 |
PCMA: PBMs Negotiating Lower Drug Prices in Medicare Part D |
| February 21 |
FDA Proposes to Strengthen Label Warning for Xolair |
| February 21 |
FDA Directs ADHD Drug Manufacturers to Notify Patients about
Cardiovascular Adverse Events and Psychiatric Adverse Events |
| February 21 |
Though Most Physicians Support a Ban on Collecting Prescribing
Information, Only a Fraction Have Used PDRP to Restrict Rx Data
Access |
| February 21 |
FDA MedWatch: Xolair (omalizumab) New Reports of Serious and
Life-Threatening Allergic Reactions (anaphylaxis) |
| February 21 |
Pennsylvania Attorney General Corbett Recovers $7.8 Million in
Settlement Funds for State's Medicaid Program |
| February 22 |
Lilly Introduces World's First Digital Insulin Pen With Memory |
| February 22 |
Emergent BioSolutions Remains Committed to Development of Enhanced
Anthrax Countermeasures |
| February 22 |
AstraZeneca Announces Investment in $120m Laboratory for Process
Research and Development at its Macclesfield Site, Cheshire, UK |
| February 22 |
Sartorius AG Combines its Biotechnology Division with Stedim
Biosystems S.A. and Becomes the Majority Owner of the Combined
Entity |
| February 22 |
Analysis of International Phase III Study of Avastin Plus
Chemotherapy Shows Improved Progression-Free Survival in Patients
With Advanced Lung Cancer |
| February 22 |
Entelos Announces Continued Research with Pfizer |
| February 22 |
Ark Wins Key Patent Case on Stroke in Europe |
| February 22 |
Survey Shows Supreme Court Ruling May Hinder IP Licensing |
| February 22 |
Lilly Introduces World's First Digital Insulin Pen With Memory |
| February 22 |
Pharmaceutical Consumers & Marketers Surveyed to Assess
Perceptions of Direct-to-Consumer Advertising in the Post-Vioxx Era |
| February 22 |
Arpida Realigns Activities to Support Transition of Its Research
Portfolio |
| February 22 |
Ikaria and Investor Group to Acquire INO Therapeutics in $670
Million Cash and Stock Merger, Creating a World Leader in Critical
Care Therapeutics |
| February 22 |
Express Scripts and PCMA Follow-On Biologics Studies Are Based on
Flawed Assumptions That Undermine Their Credibility: BIO Analysis
Raises Serious Concerns Over Two Cost Savings Studies |
| February 23 |
Danish Court Issues Preliminary Injunction That Prohibits Sale of
Generic Lipitor Product |
| February 23 |
Third Point Calls for Board to Sell Acorda Therapeutics, Inc. |
| February 23 |
Astellas and Boehringer Won the Lawsuit Against FlomaxGeneric for
Patent Infringement in the USA |
| February 23 |
FDA MedWatch: CellCept Trial Terminated Due to Increased Incidence
of Acute Rejection in Heart Transplant Patients Given
Cellcept/Rapamune |
| February 23 |
Recruitment Temporarily Suspended into C.E.R.A. Phase II Oncology
Trial |
| February 26 |
FDA Approves Cymbalta for Treatment of Generalized Anxiety Disorder |
| February 26 |
Shire and New River Pharmaceuticals Announce FDA Approval of the
First and Only Stimulant Prodrug Vyvanse (lisdexamfetamine
dimesylate) as a Novel Treatment for ADHD |
| February 26 |
Avalon Pharmaceuticals Announces the Initiation of the Primary
Screening Phase in Drug Discovery Collaboration |
| February 26 |
Novartis Committed to Making Galvus Available for Patients with
Type 2 Diabetes After US Regulators Issue ''Approvable Letter'' |
| February 26 |
Lilly Plans New Clinical Trial of Xigris |
| February 26 |
Drug Industry Increasingly Influences Breast Cancer Research |
| February 26 |
FDA MedWatch: Baraclude Risk of Developing HIV Resistance Cannot be
Excluded When Used in an HIV/HBV Co-infected Patient Not Receiving
HAART |
| February 26 |
Epix Reports Intention to Restate Financial Statements for Prior
Fiscal Periods |
| February 26 |
Inex Provides Timeline for Completing Spin-out of Tekmira
Pharmaceuticals Corporation |
| February 26 |
Graffinity and Amgen Enter into Drug Discovery Research Agreement |
| February 26 |
Bristol-Myers Squibb Company and Adnexus Therapeutics Announce
Collaboration to Develop and Commercialize Innovative Oncology
Compounds |
| February 26 |
Shire Extends Fosrenol | at Hand Program to Cover Medicare Part D
Enrollees |
| February 26 |
Azur Pharma Announces the Acquisition of Pharmelle |
| February 26 |
GSK Initiates First Global Phase III Study of Tykerb (lapatinib) in
Head and Neck Cancer |
| February 26 |
Positive Recommendation for Avastin Use in Advanced or Recurrent
Colorectal Cancer in Japan |
| February 26 |
Phase 3 Stroke Trial Shows That Novoseven Reduces Bleeding in the
Brain, but Does Not Improve Long-term Clinical Outcomes |
| February 26 |
Takeda and TAP to Promote Sucampo's Amitiza in the United States |
| February 26 |
BD Biosciences and Roche Collaborate to Advance the Study of Cell
Signal Transduction through New Phosphorylation Site Antibody
Targets and Applications |
| February 26 |
VGX Pharmaceuticals and ADViSYS Announce Merger Agreement: Creation
of VGX Immune Therapeutics Division |
| February 26 |
Inex Pharmaceuticals Submits Petition Against Protiva
Biotherapeutics |
| February 27 |
Post-Hoc Data Analyses Published in Annals of Neurology Found
Copaxone Significantly Delayed Accumulated Disability in Male
Patients with Primary Progressive Multiple Sclerosis (PPMS) |
| February 27 |
Vaccinex Announces Antibody Development and Commercialization
Alliance in Multiple Sclerosis and Oncology |
| February 27 |
Unigene Achieves $5.5 Million Milestone in Calcitonin Collaboration
for Phase III Initiation |
| February 27 |
Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial
of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its
Primary Endpoint |
| February 27 |
Judgments Granted in Favor of Chugai in Lawsuits Filed by Ajinomoto
Co., Inc. |
| February 27 |
inVentiv Health to Acquire Ignite Health, Leading Technology-Driven
Healthcare Ad Agency |
| February 27 |
Increased Prescription Drug Co-pays Linked to Lower Medication
Usage and Higher Hospitalization Rates, Thomson Medstat Study Finds |
| February 27 |
AdMedia Partners Advises Ignite Health, an Interactive Healthcare
Marketing Agency, in Acquisition by inVentiv Health |
| February 27 |
More than 300 Medicines Now in Development to Treat Rare Diseases |
| February 27 |
Mylan Provides an Update on Amlodipine Besylate Litigation |
| February 27 |
FDA Approves New Treatment For Crohn's Disease |
| February 27 |
Humira (Adalimumab) Receives FDA Approval For Treatment of Crohn's
Disease |
| February 27 |
Pfizer Wins Challenge to Norvasc Patent by Mylan |
| February 28 |
FDA Approves First Drug To Prevent and Treat Vomiting in Dogs |
| February 28 |
Merck Announces First Quarter Earnings Per Share Guidance and
Raises Full-Year 2007 Earnings Per Share Guidance |
| February 28 |
Avanir Pharmaceuticals Summarizes Outcome of FDA Meeting on Zenvia
NDA |
| February 28 |
American Heart Association Scientific Statement: AHA Statement
Recommends Doctors Change Approach to Prescribing Pain Relievers
for Patients With or at Risk for Heart Disease |
| February 28 |
Epix Pharmaceuticals Files Formal Appeal for Vasovist with the
Center for Drug Evaluation and Research |
| February 28 |
Xoma Announces Expiration of Oncology Exclusivity Obligation With
Novartis |
| February 28 |
Barr Reports GAAP Loss For Three and Six Months Ended December 31,
2006 of $3.67 Per Share and $3.18 Per Share; Adjusted Earnings For
Three and Six Months Were $0.83 Per Share and $1.70 Per Share |
| February 28 |
Alnylam Scientist Awarded Two Industry Honors |
| February 28 |
Daiichi Pharmaceutical (Beijing) Granted Sales Promotion Permission |
| February 28 |
Novo Nordisk Divests Its Ownership of Dako's Business Activities |
| February 28 |
King Pharmaceuticals Reports Year-End and Fourth-Quarter 2006
Financial Results |
| February 28 |
UCB Full-Year 2006 Financial Results |
| February 28 |
Salix Pharmaceuticals Acquires Pepcid Oral Suspension |
| February 28 |
HPV Infection Common Among Females in U.S. |
| February 28 |
Mylan Announces Launch of Quinapril Tablets, USP and Quinapril
Hydrochloride and Hydrochlorothiazide Tablets |
| February 28 |
King Pharmaceuticals Announces FDA Approval of Altace Tablet
Formulation |
| February 28 |
New Study: 'Show Me the Savings' |
